These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34648064)

  • 1. Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction.
    Seki T; Kubota Y; Matsuda J; Tokita Y; Iwasaki YK; Shimizu W
    Heart Vessels; 2022 Apr; 37(4):574-582. PubMed ID: 34648064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Clin Exp Hypertens; 2020; 42(2):110-117. PubMed ID: 30793983
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction.
    Imamura T; Kinugawa K
    Int Heart J; 2016 Sep; 57(5):600-6. PubMed ID: 27581675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical characteristics of heart failure with recovered ejection fraction].
    Luo Y; Chai K; Cheng YL; Zhu WR; Li YY; Wang H; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Apr; 49(4):333-339. PubMed ID: 33874682
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features and prognosis of patients with different types of heart failure in relation to coronary artery disease].
    Zhou Y; Mo T; Bao YP; Wang L; Zhong RR; Tian JL
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(15):1142-1147. PubMed ID: 32311877
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
    Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
    Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction.
    Kalogeropoulos AP; Fonarow GC; Georgiopoulou V; Burkman G; Siwamogsatham S; Patel A; Li S; Papadimitriou L; Butler J
    JAMA Cardiol; 2016 Aug; 1(5):510-8. PubMed ID: 27434402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
    Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.
    Quiroz R; Doros G; Shaw P; Liang CS; Gauthier DF; Sam F
    Am J Cardiol; 2014 Feb; 113(4):691-6. PubMed ID: 24484862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
    Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
    Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
    Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction.
    Vergaro G; Ghionzoli N; Innocenti L; Taddei C; Giannoni A; Valleggi A; Borrelli C; Senni M; Passino C; Emdin M
    J Am Heart Assoc; 2019 Oct; 8(20):e013441. PubMed ID: 31587602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry.
    Kang J; Park JJ; Cho YJ; Oh IY; Park HA; Lee SE; Kim MS; Cho HJ; Lee HY; Choi JO; Hwang KK; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29535141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2).
    Marui A; Nishiwaki N; Komiya T; Hanyu M; Tanaka S; Kimura T; Sakata R;
    Am J Cardiol; 2015 Aug; 116(4):580-6. PubMed ID: 26092271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes.
    Park JJ; Mebazaa A; Hwang IC; Park JB; Park JH; Cho GY
    J Am Heart Assoc; 2020 Jun; 9(12):e015009. PubMed ID: 32519555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.